Phase I Dose Escalating Study of TKI258

NCT01471548 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: TKI258

Sponsor

Novartis Pharmaceuticals